Meagan Rootman

Veriphi is an innovative medical device company that has developed a solution to verify intravenous drug identity and concentration. Globally, the cost associated with medication errors has been estimated to be US$42 billion per year. (WHO, Global Patient Safety Challenge: Medication Without Harm, 2017). Veriphi’s initial target market is intravenous oncology errors because intravenous errors are twice as likely to harm patients than drugs administered by other routes. The heart of our solution is an analyser that uses lasers to verify intravenous drug identity and concentration. Veriphi has been granted 8 US patents and 22 global patents. The Veriphi solution has applications inside the compounding pharmacy, in hospitals and at the patient’s bedside, wherever that may be. Our objective is to make intravenous cancer therapy safer, more effective, more affordable and more accessible. We believe that access to cancer treatment should not be dictated by where you live.